From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment
Objective: Major depressive disorder is the most common psychiatric disorder, worldwide,
yet response and remission rates are still unsatisfactory. The identification of genetic …
yet response and remission rates are still unsatisfactory. The identification of genetic …
Genome-wide association studies of antidepressant outcome: a brief review
G Laje, FJ McMahon - Progress in Neuro-Psychopharmacology and …, 2011 - Elsevier
Genome-wide association studies (GWAS) of antidepressant treatment outcome have been
at the forefront of psychiatric pharmacogenetics. Such studies may ultimately help match …
at the forefront of psychiatric pharmacogenetics. Such studies may ultimately help match …
Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research
C Fabbri, G Di Girolamo… - American Journal of …, 2013 - Wiley Online Library
Major depressive disorder (MDD) is an emergent cause of personal and socio‐economic
burden, both for the high prevalence of the disorder and the unsatisfying response rate of …
burden, both for the high prevalence of the disorder and the unsatisfying response rate of …
Progress and prospects in pharmacogenetics of antidepressant drugs
C Fabbri, C Crisafulli, M Calabrò, E Spina… - Expert Opinion on …, 2016 - Taylor & Francis
Introduction: Depression is responsible for the most part of the personal and socio-economic
burden due to psychiatric disorders. Since antidepressant response clusters in families …
burden due to psychiatric disorders. Since antidepressant response clusters in families …
Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications
C Fabbri, A Serretti - Current psychiatry reports, 2015 - Springer
The pharmacogenetics of antidepressants has been not only a challenging but also
frustrating research field since its birth in the 1990s. Indeed, great expectations followed the …
frustrating research field since its birth in the 1990s. Indeed, great expectations followed the …
[HTML][HTML] Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level …
KE Tansey, M Guipponi, N Perroud, G Bondolfi… - 2012 - journals.plos.org
Background It has been suggested that outcomes of antidepressant treatment for major
depressive disorder could be significantly improved if treatment choice is informed by …
depressive disorder could be significantly improved if treatment choice is informed by …
[HTML][HTML] Pharmacogenetics of antidepressants
C Crisafulli, C Fabbri, S Porcelli, A Drago… - Frontiers in …, 2011 - frontiersin.org
Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and
up to 30% do not respond at all. Genetic factors contribute for about 50% of the AD …
up to 30% do not respond at all. Genetic factors contribute for about 50% of the AD …
Pharmacogenetics of antidepressant response: a polygenic approach
J García-González, KE Tansey, J Hauser… - Progress in Neuro …, 2017 - Elsevier
Background Major depressive disorder (MDD) has a high personal and socio-economic
burden and> 60% of patients fail to achieve remission with the first antidepressant. The …
burden and> 60% of patients fail to achieve remission with the first antidepressant. The …
Genetics and personalized medicine in antidepressant treatment
Background: Antidepressant medication is a major cornerstone in treatment of mood and
anxiety disorders. Numerous substances are available on the market; however, only 60% of …
anxiety disorders. Numerous substances are available on the market; however, only 60% of …
Pharmacogenetics of antidepressant response
Personalized medicine—the adaptation of therapies based on an individual's genetic and
molecular profile—is one of the most promising aspects of modern medicine. The …
molecular profile—is one of the most promising aspects of modern medicine. The …